Deka Bank Deutsche Girozentrale Arbutus Biopharma Corp Transaction History

Deka Bank Deutsche Girozentrale

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	SELL	$2.24 - $3.06 $224,000 - $306,000	-100,000 Reduced 40.0%	150,000 $331,000
Q3 2020 Oct 29, 2020	BUY	$1.75 - $6.2 $437,500 - $1.55 Million	250,000 New	250,000 $766,000
Q3 2019 Nov 14, 2019	SELL	$1.34 - $2.4 $76,380 - $136,800	-57,000 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$1.46 - $4.44 $32,850 - $99,900	22,500 Added 65.22%	57,000 $129,000
Q1 2019 May 10, 2019	BUY	$3.41 - $4.57 $20,460 - $27,420	6,000 Added 21.05%	34,500 $311,000
Q4 2018 Feb 12, 2019	SELL	$3.5 - $9.66 $21,000 - $57,960	-6,000 Reduced 17.39%	28,500 $105,000
Q1 2018 May 03, 2018	BUY	$4.4 - $6.05 $151,800 - $208,725	34,500 New	34,500 $174,000

138

95.5M

3.44M

377K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $577M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.